SEES Bethesda
Date: November 13, 2026 Time: 9:00am - 1:00pm Location: National Institutes of Health 9000 Rockville Pike • Bethesda, Maryland • 20892 Cost: FREE to attend
Join us at the National Institutes of Health (NIH) for our final SEES event of 2026!
Living with neuroendocrine (NET) cancer is about more than medical treatment, it’s about caring for the whole person.
Led by Dr. Eric Liu and Dr. Jaydira Del Rivero, Our SEES program is bringing together leading experts in Sleep, Nutrition, Exercise, and Spirit to share practical tools and meaningful guidance designed to positively impact your daily life while living with NET cancer.
This special event at NIH will offer an opportunity to learn from dedicated specialists, connect with others in the NET community, and focus on your overall well-being—whether you are newly diagnosed, currently in treatment, or living long-term with NET.
You’ll leave with practical information, valuable resources, and renewed encouragement to support your journey.
OUR PANELISTS
Eric Liu, MD, FACS
Dr. Eric Liu is a renowned surgeon specializing in neuroendocrine disease and the co-founder of the Healing NET Foundation. He established the first U.S. clinical trial for the Gallium 68 PET scan to diagnose neuroendocrine tumors and trained at the world-leading Neuroendocrine Center of Excellence in Sweden. Dr. Liu lectures nationwide and specializes in treating neuroendocrine cancers and performing advanced abdominal surgeries at the Intermountain Health Cancer Center – Saint Joseph. A Harvard and Columbia alumnus, he has earned numerous accolades, including the National Cancer Institute’s Paul Calabresi Award for Clinical Oncology.
Jaydira Del Rivero, MD
Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma.
